Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
Department of Radiology, Cantonal Hospital Baden, Baden, Switzerland; Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland.
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):987-996. doi: 10.1016/j.ijrobp.2017.11.037. Epub 2017 Dec 1.
To assess the rate of radiation necrosis (RN) and white matter lesions (WMLs) in pediatric patients with primary brain tumors treated with pencil beam scanning (PBS) proton therapy (PT) with or without concomitant chemotherapy at the PSI.
Between 1999 and 2015, 171 pediatric patients (age <18 years) were treated with PT. Median age at diagnosis was 3.3 years (range, 0.3-17.0 years), and the median delivered dose was 54 Gy (relative biological effectiveness) (range, 40.0-74.1 Gy). Radiation necrosis and WMLs were defined as a new area of abnormal signal intensity on T2-weighted images or increased signal intensity on T2-weighted images, and contrast enhancement on T1 occurring in the brain parenchyma included in the radiation treatment field, which did not demonstrate any abnormality before PT. Radiation necrosis and WMLs were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. The median follow-up period for the surviving patients was 49.8 months (range, 5.9-194.7 months).
Twenty-nine patients (17%) developed RN at a median time of 5 months (range, 1-26 months), most of them (n = 17; 59%) being asymptomatic (grade 1). Grade 2, 4, and 5 toxicities occurred in 8, 2, and 2 patients, respectively. Eighteen patients (11%) developed WMLs at a median time of 14.5 months (range, 2-62 months), most of them (n = 13; 72%) being asymptomatic (grade 1). White matter lesion grade 2 and 3 toxicities occurred in 4 and 1 patient(s), respectively. The 5-year RN-free and WML-free survival was 83% and 87%, respectively. In univariate analysis, neoadjuvant (P = .025) or any (P = .03) chemotherapy, hydrocephalus before PT (P = .035), and ependymoma (P = .026) histology were significant predictors of RN.
Children treated with PT demonstrated a low prevalence of symptomatic RN (7%) or WML (3%) compared with similar cohorts treated with either proton or photon radiation therapy. Chemotherapy, ependymomal tumors and hydrocephalus as an initial symptom were significant risk factors for RN.
评估在 PSI 采用笔形束扫描(PBS)质子治疗(PT)联合或不联合化疗治疗的原发性脑肿瘤儿科患者的放射性坏死(RN)和脑白质病变(WML)的发生率。
1999 年至 2015 年间,171 名儿科患者(年龄<18 岁)接受了 PT 治疗。中位诊断年龄为 3.3 岁(范围,0.3-17.0 岁),中位剂量为 54 Gy(相对生物效应)(范围,40.0-74.1 Gy)。放射性坏死和脑白质病变定义为在包含在放射治疗野中的脑实质中出现新的异常信号强度的区域,或 T2 加权图像上的信号强度增加,以及 T1 上的对比增强,而在 PT 之前没有任何异常。放射性坏死和脑白质病变根据不良事件的通用术语标准,版本 4.0 进行分级。生存患者的中位随访时间为 49.8 个月(范围,5.9-194.7 个月)。
29 名患者(17%)在中位时间 5 个月(范围,1-26 个月)后出现 RN,其中大多数(n=17;59%)无症状(1 级)。2 级、4 级和 5 级毒性分别发生在 8、2 和 2 名患者中。18 名患者(11%)在中位时间 14.5 个月(范围,2-62 个月)后出现 WML,其中大多数(n=13;72%)无症状(1 级)。4 名和 1 名患者出现 WML 2 级和 3 级毒性。5 年的 RN 无进展和 WML 无进展生存率分别为 83%和 87%。在单变量分析中,新辅助(P=0.025)或任何化疗(P=0.03)、PT 前脑积水(P=0.035)和室管膜瘤(P=0.026)组织学是 RN 的显著预测因素。
与接受质子或光子放射治疗的类似队列相比,接受 PT 治疗的儿童的症状性 RN(7%)或 WML(3%)发生率较低。化疗、室管膜瘤和脑积水作为首发症状是 RN 的显著危险因素。